Why Celldex Therapeutics, Inc.’s (CLDX) Stock Is Down 5.24%
As of Wednesday, July 22, Celldex Therapeutics, Inc.’s CLDX share price has dipped by 5.24%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Commentary & Analysis
Why Celldex Therapeutics, Inc.’s (CLDX) Stock Is Down 5.90%
As of Thursday, July 16, Celldex Therapeutics, Inc.’s CLDX share price has dipped by 5.90%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Celldex Therapeutics, Inc.’s (CLDX) Stock Is Up 6.04%
As of Tuesday, March 31, Celldex Therapeutics, Inc.’s CLDX share price has surged by 6.04%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Celldex Therapeutics, Inc.’s (CLDX) Stock Is Up 10.02%
As of Monday, March 23, Celldex Therapeutics, Inc.’s CLDX share price has surged by 10.02%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Celldex Therapeutics, Inc.’s (CLDX) Stock Is Down 5.67%
As of Thursday, March 12, Celldex Therapeutics, Inc.’s CLDX share price has dipped by 5.67%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | CLDX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,171.0 | $292.6 | 60% |
|
| Shares Out (Mil) | 77.8 | 54.4 | 57% |
|
| Institutional Ownership | 99.8% | 93.2% | 94% |
|
| Float (Mil) | 73.0 | 40.2 | 55% |
|
| Beta | 0.84 | 0.94 | 50% |
|
| Avg Daily Volume (000s) | 947 | 544 | 69% |
|
| Price Change (52-week) |
93.3% | 59.7% | 89% |
|
| Growth | CLDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (27.3%) | 13.6% | 1% |
|
| Net Income (5yr) | (34.0%) | (10.1%) | 12% |
|
| EPS (5yr) | (14.1%) | 16.0% | 19 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (60.9%) | (15.6%) | 4% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 11 | |
| Current EPS | ($1.005) | ($4.106) | ($4.162) | |
| Month Ago EPS | ($1.081) | ($4.392) | ($4.500) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($1.080) | ($4.390) | ($4.548) | |
| Year/Year Chg | 6.5% | 5.4% | (8.8%) | |
| Financials | CLDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $37 | 0% |
|
| Net Income (TTM) (Mil) | ($301) | ($43) | 5% |
|
| EPS (TTM) | ($4.334) | ($1.400) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($236) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $24 | $2 | 64% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 22% |
|
| Enterprise Value (Q1) (Mil) | $2,563 | $164 | 52% |
|
| Valuation | CLDX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.44 | 2.83 | 75% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CLDX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (40.8%) | (47.5%) | 14% |
|
| ROE | (43.9%) | (55.0%) | 17% |
|
| Liabilities to Assets | 8.7% | 29.6% | 5% |
|
| F-Score | 1 | 3 | 1% |
|
Passing Stock Screens
As of 8/21/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Up 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 22.7% |
| +/- S&P 500: | +15.2 |
